CTLT Technical Analysis



As of date:5/24/2024
CTLT stock price:54.82
CTLT 50 DMA:56.02
CTLT 200 DMA:48.91
CTLT MACD (200-50):-7.11
CTLT RSI:20.75
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)20.75
Extremely
Oversold

Also see:
CTLT Market Cap History
CTLT Shares Outstanding History
CTLT YTD Return

Quotes delayed 20 minutes

Email EnvelopeFree CTLT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Notable Two Hundred Day Moving Average Cross - MDXG
48 minutes ago


FIBK Crosses Below Key Moving Average Level
48 minutes ago


South Plains Financial Breaks Below 200-Day Moving Average - Notable for SPFI
49 minutes ago


Bullish Two Hundred Day Moving Average Cross - BHRB
1 hour, 2 minutes ago


CoStar Group Breaks Below 200-Day Moving Average - Notable for CSGP
1 hour, 3 minutes ago


ConnectOne Bancorp (CNOB) Shares Cross Below 200 DMA
1 hour, 7 minutes ago


VALU Makes Bullish Cross Above Critical Moving Average
1 hour, 7 minutes ago


MAA Crosses Below Key Moving Average Level
1 hour, 11 minutes ago


Direxion Daily 20+ Year Treasury Bear 3X Shares (TMV) Shares Cross Above 200 DMA
1 hour, 11 minutes ago


Notable Two Hundred Day Moving Average Cross - BIV
1 hour, 11 minutes ago


Notable Two Hundred Day Moving Average Cross - SPAB
1 hour, 12 minutes ago


Baytex Energy Breaks Above 200-Day Moving Average - Bullish for BTE.CA
1 hour, 12 minutes ago


iShares Core 10+ Year USD Bond Breaks Below 200-Day Moving Average - Notable for ILTB
1 hour, 12 minutes ago


CP.CA Crosses Below Key Moving Average Level
1 hour, 12 minutes ago


IYR Makes Notable Cross Below Critical Moving Average
1 hour, 12 minutes ago


More Technical Analysis News

CTLT Technical AnalysisCTLT RSI
Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.

When researching a stock like Catalent, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from CTLT Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for CTLT stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
CTLT DMACTLT MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Catalent (CTLT) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

CVS Technical Analysis
DGX Technical Analysis
DHR Technical Analysis
DVA Technical Analysis
DXCM Technical Analysis
EW Technical Analysis
GEHC Technical Analysis
GILD Technical Analysis
HCA Technical Analysis
HOLX Technical Analysis
More Healthcare companies »

 

CTLT Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2024, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.